CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay, M Lazzari, V Facchinetti… - Blood, The Journal …, 2001 - ashpublications.org
Complement-dependent cytotoxicity is thought to be an important mechanism of action of the
anti-CD20 monoclonal antibody rituximab. This study investigates the sensitivity of freshly …
anti-CD20 monoclonal antibody rituximab. This study investigates the sensitivity of freshly …
A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia
P Strati, WG Tong, C Vitale, WG Wierda… - Leukemia & …, 2015 - Taylor & Francis
Rituximab monotherapy has been associated with lower response rates in chronic
lymphocytic leukemia (CLL) when compared to other CD20 positive lymphoproliferative …
lymphocytic leukemia (CLL) when compared to other CD20 positive lymphoproliferative …
Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia
J Weitzman, M Betancur, L Boissel… - Leukemia & …, 2009 - Taylor & Francis
Monoclonal antibodies (mAbs) are increasingly used in treatment protocols for chronic
lymphocytic leukemia (CLL). Here we determined (i) the extent of antibody-dependent …
lymphocytic leukemia (CLL). Here we determined (i) the extent of antibody-dependent …
Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion
M Borsky, V Hrabcakova, J Novotna, Y Brychtova… - Leukemia Research, 2021 - Elsevier
The in vivo rituximab effects in B cell malignancies are only partially understood. Here we
analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n= 80) the inter-patient …
analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n= 80) the inter-patient …
[HTML][HTML] Results of a phase II randomizing intensified rituximab pre-phase followed by standard FCR Vs standard FCR in Previously untreated patients with active b …
S Lepretre, R Letestu, C Dartigeas, H Maisonneuve… - Blood, 2014 - Elsevier
Introduction: Rituximab dosing regimen is largely empirical in CLL patients and phase I
study has suggested a dose response relationship in previously treated CLL patients …
study has suggested a dose response relationship in previously treated CLL patients …
Rituximab Plus GM-CSF for Patients with Chronic Lymphocytic Leukemia.
A Ferrajoli, SM O'Brien, SH Faderl, WG Wierda… - Blood, 2005 - Elsevier
Abstract Treatment with single agent rituximab is associated with overall response (OR) rate
of 15–35% in previously treated patients and up to 44% in untreated patients with CLL. The …
of 15–35% in previously treated patients and up to 44% in untreated patients with CLL. The …
Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia
JP Quinn, S Mohamedbhai, K Chipperfield… - Leukemia & …, 2008 - Taylor & Francis
The optimal salvage treatment for patients with chronic lymphocytic leukemia (CLL) who
have failed or relapsed shortly after treatment with purineanalogue based treatment remains …
have failed or relapsed shortly after treatment with purineanalogue based treatment remains …
[HTML][HTML] Rituximab in combination with bendamustine or chlorambucil for treating patients with chronic lymphocytic leukemia: interim results of a phase IIIb study …
V Leblond, K Laribi, O Ilhan, M Aktan, A Unal… - Blood, 2012 - Elsevier
Abstract 2744 The current standard of care for fit patients (pts) with chronic lymphocytic
leukemia (CLL) is rituximab (R) in combination with fludarabine and cyclophosphamide; …
leukemia (CLL) is rituximab (R) in combination with fludarabine and cyclophosphamide; …
Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro
A Furlan, F Villanova, F Pietrogrande… - Leukemia & …, 2010 - Taylor & Francis
Rituximab maintenance therapy provides a significant benefit in patients with indolent B-cell
non-Hodgkin lymphoma (NHL). Based on its efficacy in improving response to …
non-Hodgkin lymphoma (NHL). Based on its efficacy in improving response to …
Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia
DT Alexandrescu, PH Wiernik - Medical Oncology, 2008 - Springer
An important biological alteration in chronic lymphocytic leukemia (CLL) is the dysregulation
of immunoglobulin production, as a consequence of complex and yet incompletely …
of immunoglobulin production, as a consequence of complex and yet incompletely …